Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 4
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
Progression-free survival at 12 months was 47.7% (95% CI, 41.8 to 53.2) with relatlimab-nivolumab as compared with 36.0% (95% CI, 30.5 to 41.6) with nivolumab. Progression-free survival across key subgroups favored relatlimab-nivolumab over nivolumab. Grade 3 or 4 t …
Progression-free survival at 12 months was 47.7% (95% CI, 41.8 to 53.2) with relatlimab-nivolumab as compared with 36.0% (95% CI, 30. …
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Amaria RN, et al. Nature. 2022 Nov;611(7934):155-160. doi: 10.1038/s41586-022-05368-8. Epub 2022 Oct 26. Nature. 2022. PMID: 36289334 Free PMC article. Clinical Trial.
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma(1). ...Patients received two neoadjuvant doses (nivolumab 480 mg and relatlimab 160 mg intravenously ever …
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unr …
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ. Ascierto PA, et al. J Clin Oncol. 2023 May 20;41(15):2724-2735. doi: 10.1200/JCO.22.02072. Epub 2023 Feb 13. J Clin Oncol. 2023. PMID: 36780608 Free PMC article.
PURPOSE: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated significantly improved progression-free survival (P …
PURPOSE: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death li …
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
Albrecht LJ, Livingstone E, Zimmer L, Schadendorf D. Albrecht LJ, et al. Curr Oncol Rep. 2023 Jun;25(6):647-657. doi: 10.1007/s11912-023-01406-4. Epub 2023 Apr 1. Curr Oncol Rep. 2023. PMID: 37004702 Free PMC article. Review.
Therefore, other combination partners that also lead to high and long-lasting responses but cause fewer adverse events were explored. RECENT FINDINGS: Relatlimab, a LAG-3 blocking antibody, was investigated in combination with nivolumab in a phase 2/3 randomized dou …
Therefore, other combination partners that also lead to high and long-lasting responses but cause fewer adverse events were explored. …
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY.
Raschi E, Comito F, Massari F, Gelsomino F. Raschi E, et al. Immunotherapy. 2023 Feb;15(2):85-91. doi: 10.2217/imt-2022-0172. Epub 2023 Jan 11. Immunotherapy. 2023. PMID: 36628573 Review.
With the recent regulatory approvals, the relatlimab-nivolumab combination brings new expectations and opens avenues toward effective immunotherapy combination in advanced melanoma. This work provides a critical insight into the recent phase II-III RELATIVITY-047 trial (NC …
With the recent regulatory approvals, the relatlimab-nivolumab combination brings new expectations and opens avenues toward effective …
Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B, Burns M, Pervanas H, Ciurescu D, Dima L. Thomas B, et al. Am J Ther. 2023 Nov-Dec 01;30(6):e526-e534. doi: 10.1097/MJT.0000000000001680. Am J Ther. 2023. PMID: 37921680 Clinical Trial.
Volume of distribution is 6.6 L for relatlimab and nivolumab, and half-life is 27 and 26 days, respectively. ...The exposure-response relationship and pharmacodynamic response for the safety and effectiveness of nivolumab/relatlimab-rmbw have not been fully characte …
Volume of distribution is 6.6 L for relatlimab and nivolumab, and half-life is 27 and 26 days, respectively. ...The exposure-response …
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
Menzies AM, Pires da Silva I, Trojaniello C, Vieu E, Amaria RN, Zimmer L, Lo SN, Burton EM, Tawbi HA, Schadendorf D, Grob JJ, Ascierto PA, Long GV. Menzies AM, et al. N Engl J Med. 2022 Apr 28;386(17):1668-1669. doi: 10.1056/NEJMc2119768. N Engl J Med. 2022. PMID: 35476655 No abstract available.
Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips AL, Reeves DJ. Phillips AL, et al. Ann Pharmacother. 2023 Jun;57(6):738-745. doi: 10.1177/10600280221131396. Epub 2022 Oct 21. Ann Pharmacother. 2023. PMID: 36268952 Review.
The PFS benefits appear greatest in those with programmed cell death-ligand 1 (PD-L1) <1% and lymphocyte activation gene-3 (LAG-3) 1%. Adverse effects commonly experienced were immune related in nature and require early identification and prompt management. Grade …
The PFS benefits appear greatest in those with programmed cell death-ligand 1 (PD-L1) <1% and lymphocyte activation gene-3 (LAG-3) 1%. …
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
Koseła-Paterczyk H, Rutkowski P. Koseła-Paterczyk H, et al. Expert Opin Biol Ther. 2023 May;23(5):383-388. doi: 10.1080/14712598.2023.2215922. Epub 2023 May 24. Expert Opin Biol Ther. 2023. PMID: 37200112
However, the use of this immunotherapy combination is limited in routine practice to approximately half of the patients due to high toxicity with the majority of patients at risk of severe adverse events. The current efforts are to determine how best to integrate combinati …
However, the use of this immunotherapy combination is limited in routine practice to approximately half of the patients due to high toxicity …
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D, Tawbi H, Lipson EJ, Stephen Hodi F, Rutkowski P, Gogas H, Lao CD, Grob JJ, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV. Schadendorf D, et al. Eur J Cancer. 2023 Jul;187:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22. Eur J Cancer. 2023. PMID: 37167764 Free article. Clinical Trial.
BACKGROUND: In the phase II/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO + RELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-free survival (PFS) ver …
BACKGROUND: In the phase II/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO + RELA; …
11 results